exhibit 10. 1 termination agreement re biologics distribution agreement this “ termination agreement re biologics distribution agreement ” ( this “ agreement ” ) is executed as of this 22nd day of august, 2007 by and between mckesson corporation, a delaware corporation ( “ mckesson ” ) and accentia biopharmaceuticals, inc., a florida corporation ( “ accentia ” ) based on the following facts and understandings : recitals a. mckesson and accentia are parties to that certain “ biologics distribution agreement ” ( the “ bda ” ) dated as of february 27, 2004. b. pursuant to the bda, accentia is indebted to mckesson for certain unliquidated payment obligations that currently exceed $ 3, 000, 000. c. all obligations of accentia under the bda, including the payment obligations, are secured and / or guaranteed by the following ( among other things ) : i. all of accentia ’ s personal property, wherever located and whether now existing or owned or hereafter acquired or arising, including all accounts, chattel paper, commercial tort claims, deposit accounts, documents, equipment ( including all fixtures ), general intangibles, intellectual property, patents, trademarks, service marks, trade names, trade secrets, customer lists, copyrights, payment intangibles, instruments, inventory, investment property ( including but not limited to all stock it holds in teamm pharmaceuticals, inc. and the analytica group, inc. and biovest inc., 1 called the “ subsidiary stock ” ), membership interests, letter - of - credit rights, money and all products, proceeds and supporting obligations of any and all of the foregoing ( the “ accentia collateral ” ) ; ii. certain shares of capital stock in biodelivery sciences international, inc. ( the “ bdsi stock ” ) and in star scientific, inc. ( the “ ssi stock ” ) owned by either regent court technologies ( a limited liability company of which francis e. o ’ donnell, jr., m. d. is the managing member and which is referred to as “ rct ” ) or hopkins capital group ii, llc ( a limited liability company of which francis e. o ’ donnell, jr., m. d. is a manager and which is referred to as “ hcg ii ” ), as more fully described on